Xeris Biopharma Holdings Inc
XERS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.01B
Close$
$2.89
82.6% downside
Current Fair Value
82.6% downsideOvervalued by 82.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.01 Billion |
|---|---|
| Enterprise Value | $3.11 Billion |
| Earnings per Share | $0 |
| Beta | 0.84 |
| Outstanding Shares | 180,941,748 |
Return
| Return on Equity | -13.32% |
|---|---|
| Return on Assets | -1.53% |
| Return on Invested Capital | 4.36% |
Valuation & Multiples
| P/E Ratio | -379.05 |
|---|---|
| PEG | -22.06 |
| Price to Sales | 8.33 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.44 |
| Enterprise Value to EBIT | 246.86 |
| Enterprise Value to Net Income | -479 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 4.63 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS
$0.06
Est. $0.03Revenue
$107.22 M
Est. $101.68 MNext Earnings Call
Expected Date
March 1, 2027
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$119.03 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 64.35% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.14%▼ 56.36% |
|---|---|
| Total Invested | $118.16M▼ 86.40% |
| Investors Holding | 84▼ 167.00% |
About Xeris Pharmaceuticals Inc
435 employees
CEO: paul Edick
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering, developing, and commercializing medical treatments for individuals suffering from conditions in endocrinology, neurology, and ...